As a result, recent European Society of Cardiology (ESC) heart failure guidelines now recommend SGLT2 inhibitors as a Class I, Level A therapy for patients with heart failure with reduced ejection fraction, irrespective of diabetes status [20]. The gene discussed is SLC5A2; the disease is heart failure.